Treatments using venlafaxine
US6310101A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 2, 1999 |
| Grant date | Oct 30, 2001 |
| Priority date | — |
| Expiry date | Apr 2, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase disphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula: ##STR1## in which A is a moiety of the formula ##STR2## where PA1 the dotted line represents optional unsaturation; PA1 R.sub.1 is hydrogen or alkyl; PA1 R.sub.2 is alkyl; PA1 R.sub.4 is hydrogen, alkyl, formyl, or alkanol; PA1 R.sub.5 and R.sub.6 are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy; PA1 R.sub.7 is hydrogen or alkyl; and PA1 n is 0, 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.